SNIPR BIOME

Focus: SNIPR Biome is a Copenhagen-based pre-revenue biotech specializing in CRISPR-based microbiome therapeutics and genetically-modified bacteriophages, currently operating at under 50 employees.

Gene Therapy Rare Diseases Gastroenterology

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Funding Stage

SERIES A

Employees

1-50

Total Funding

$50M

Open Jobs

About SNIPR BIOME

AI assessmentNot Hiring

No open roles listed right now. Follow SNIPR BIOME to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

SNIPR001

E.Coli Infections

PHASE_1

Clinical Trials (1)

NCT05277350A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects

Phase 1

Help build intelligence for SNIPR BIOME

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity in emerging CRISPR microbiome space with novel bacteriophage platform before Series B scaling
Series A stage provides equity upside potential before revenue generation and institutional capital influx
Focused pipeline in high-unmet-need areas (rare diseases, gastroenterology) with differentiated modality vs. traditional pharma

Watch Out For

No active job openings currently listed, indicating potential resource constraints or hiring freeze at early stage
Extremely early-stage pipeline (Phase 1/1-2 only) with 2-7+ years minimum to meaningful readouts; high scientific and commercial risk
Undisclosed funding amount and no revenue creates significant cash runway uncertainty; pre-Series B closure risk

Generated by Claude from SNIPR BIOME's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

SNIPR001 consists of genetically modified bacteriophages specifically targeting Escherichia coli

E Coli Infections

PHASE_1_2

Clinical Trials (1)

NCT06938867Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant

Phase 1/2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 2 clinical trials

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo